Reuters logo
BRIEF-Seres Therapeutics Q3 net loss per share ‍$0.17​
2017年11月8日 / 中午12点15分 / 10 天前

BRIEF-Seres Therapeutics Q3 net loss per share ‍$0.17​

Nov 8 (Reuters) - Seres Therapeutics Inc:

* Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress

* Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​

* Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​

* Seres Therapeutics Inc qtrly net loss per share ‍$0.17​

* Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below